BCL11A and B-cell non-Hodgkin lymphoma: This therapy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR to edit the patient's hematopoietic stem cells, enabling them to produce fetal hemoglobin by altering the B-cell lymphoma/leukemia (BCL11A) gene [32].